Surgery for Grave’s Disease by Singh, Kul Ranjan & Mishra, Anand Kumar
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Surgery for Grave’s Disease
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Abstract
Graves’ disease (GD) is the commonest cause of hyperthyroidism followed by 
toxic nodular goitre. Patients presenting as goitre with clinical features of hyperthy-
roidism are to be carefully evaluated with biochemically with thyroid stimulating 
hormone (TSH), free thyroxine (fT4) and radionuclide scan (Technitium-99/
Iodine-123). Those with GD also have raised thyroid receptor stimulating antibody 
levels. Patients are simultaneously evaluated for eye disease and managed accord-
ingly. Initial treatment is rendering patient euthyroid using anti thyroid drugs 
(ATD) and if remission does not occur either continue medical therapy or proceed 
for definitive therapy by radioactive iodine ablation (RAI) or surgery. In last 
decades there is ample literature preferring surgery as preferred definitive therapy. 
Surgery in thyroid disease has become safer with development of many intra-
operative adjuncts but it should be performed by high volume thyroid surgeon. The 
procedure of choice is near total or total thyroidectomy as it avoids recurrences. 
Patients who are not eligible or willing for surgery can be managed with RAI.
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1. Introduction
Grave’s disease (GD) is the commonest cause of hyperthyroidism world over 
representing more than 50% of hyperthyroid patients [1]. A woman is 7–10 times 
more likely to be affected by it [2] . The incidence of autoimmune thyroid diseases 
like GD and Hashimoto’s thyroiditis is on the rise in tropical countries probably 
due to environmental immunological factors [3]. GD has systemic manifestations. 
Eyes’s are involved to variable extent in more than half the patients. Treatment 
aims to restore to the thyroid hormones to normal levels along with achieving 
remission and care of ophthalmological manifestations. Anti-thyroid drugs (ATD), 
Radioactive Iodine (RAI) and surgery are the current modalities of treatment [1]. 
They have their unique indications, advantages, disadvantages and complications. 
ATD are the usual first line of treatment. Relapsing patients or GD with certain co 
existing conditions may require a definitive treatment. RAI or surgery are indicated 
in such patients. The choice of definitive therapy depends on the patient and treat-
ing physician. Patients involvement in decision making has been associated with 
increased patients satisfaction [4, 5].
2. Epidemiology and pathogenesis
The peak incidence of GD is observed between 30 to 50 years of age. Annual 
reported incidence of GD is 50 and of ophthalmopathy is 16 per 100000 population. 
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Orbital imaging if performed in all patients of GD will reveal changes of ophthal-
mopathy in upto 70% of patients. Approximately 3% of women and 0.5% of men 
during their life time can develop GD [6].
GD is an organ specific auto immune disease caused by thyroid stimulating 
hormone receptor (TSHR) circulating stimulating auto antibodies. The TSHR 
stimulating antibody binds to leucine rich extracellular domain of TSHR on surface 
of thyrocytes and orbital fibroblasts and IGF1 receptors. After binding it increases 
production of intracellular cyclic AMP causing thyrocyte growth and increased 
thyroid hormone production.
3. Diagnosis
Measurement of Free T4/Free T3 and TSH is the initial diagnostic test. In overt 
hyperthyroidism FT4 and FT3 are elevated but in milder hyperthyroidism FT4 may 
be normal with only FT3 elevation. TSH R antibody is sensitive (97%) and specific 
(98%) tool for accurate diagnosis of GD [7]. High resolution ultrasound reveals dif-
fuse goiter and hypoechogenicity. Diagnosis is confirmed by thyroid scintigraphy by 
Tc 99 pertechnatate or I 123 scintigraphy. Scintigraphy is definitely needed for diagnosis.
4. Treatment options
Anti-thyroid drugs (ATD) are used in the initial management of GD with aim to 
achieve euthyroidism. Once patient is euthyroid it should be maintained to achieve 
remission. About half of the patients go into remission after 18 to 24 months of treat-
ment with ATD. Patients without remission and recurrent disease (30–40% in the 
first 12 months and approximately 50–60% in long term) require definitive therapy. 
Definitive therapy is either surgical or medical ablation of all thyrocytes. The options 
are radioactive iodine (RIA) or thyroidectomy. After ablative therapy thyroid hor-
mone replacement is provided to control hypothyroidism. There are reports of use 
of long term ATD to achieve remission. Choice between RIA and thyroidectomy are 
influenced by physician, patient, institutional and geographical beliefs and practice 
patterns. The most “effective” therapy for both physician’s and patient perspective 
will be which will provide rapid euthyroidism and prevent recurrences.
Early and rapid euthyroidism is desirable in all GD patients as it decreases 
mortality and halts eye disease progression. In a retrospective cohort study of 4189 
GD patients regardless of the method of treatment, low TSH at 1 year following 
GD diagnosis was associated with a 55% increase in cardiovascular mortality (atrial 
fibrillation, heart failure, pulmonary hypertension, angina pectoris, and stroke) 
[8]. Lillevang et al. in a cohort study of 235,547 individual investigated association 
between hyperthyroidism and mortality in both treated and untreated groups and 
concluded that decreased TSH increases mortality in both groups and with every 
duration of 6 months of suppressed TSH was associated with 11–13% increase in 
total mortality [9]. Dale et al. found that even transient hypothyroidism during 
treatment was associated with greater weight-gain during medical treatment in 162 
consecutive hyperthyroid patients [10]. Even consensus statement of the European 
Group on Graves’ orbitopathy (EUGOGO) recommends avoidance of hypothyroid-
ism as it can cause exacerbation of thyroid eye disease [11].
Thyroidectomy is the only modality of treatment which can provide both rapid 
euthyroidism and prevent recurrence. There are reports of RAI worsening GD 
ophthalmopathy [12, 13]. In a systematic review of literature between 2001 and 
2011which included retrospective and prospective studies (14,245 patients) on the 
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comparison of RAI and surgery as best definitive treatment for GD, reported surgery 
to be 3.44 times more likely to be successful than RAI (P < .001). And total thyroid-
ectomy (TT) was 95.45 times more successful than RAI (P < .001) and concluded 
thyroidectomy as the most successful modality for the management of GD. [14].
5. Thyroidectomy
Thyroidectomy has been performed for GD since 19th century. However, the 
earlier years were fraught with significant morbidity and mortality. Introduction 
of RAI resulted in a rapid decline in popularity of thyroidectomy for GD. 
Improvements in medical management and refinements in surgical techniques 
along with knowledge of long term effects of RAI has renewed interests in surgery 
and it is re gaining the lost grounds [15–17].
6. Indications for surgery
Surgery is the treatment of choice in those with compressive symptoms attrib-
utable to goiter, large goiters, presence/suspicion of co-existing malignancy, GD 
with non-malignant nodule with no/reduced uptake of RAI which is large in size, 
co-existing parathyroid pathology. Those lactating, pregnant or desirous of preg-
nancy within next 6 months and presence of significant active ophthalmopathy are 
advised surgery [5, 18–20]. Pediatric patients failing ATD are more likely to undergo 
thyroidectomy compared to RAI [21]. Intolerance/non-compliance to ATD, patient 
preference is an indication in themselves for surgery as treatment of choice.
Indications of thyroidectomy in GD patients include following (6C’s):
1. ATD Contraindicated: Difficulty with adequate hormonal control on medica-
tions, or Intolerance, or recurrence after ATD treatment
2. RAI Contraindicated: pregnant and nursing women, Large goiter with or with-
out compressive symptoms (dysphagia, dysphonia, dyspnoea), Relatively low 
uptake of RAI, associated thyroid nodule with confirmed or suspected thyroid 
malignancy,
3. Coexisting moderate-to-severe active Graves’ orbitopathy
4. Associated Coexiting disease: periodic paralysis
5. Other Conditions: Young or pediatric patients, women planning a pregnancy 
within 6 months, refusal or lack of facilities for RAI, individual preference 
for surgery
6. Cigrette Smokers (increased risk of exacerbation of eye disease after definitive 
treatment with radioactive iodine).
7. Advantages of surgery
Surgery is considered the most effective treatment for GD. It results in prompt 
control of hyperthyroidism. Co-existing thyroid nodules a subset of which may be 
harboring malignancy are treated concurrently by surgery [22]. Surgery is said to have 
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the best ophthalmological outcome in ophthalmopathy compared to ATD and RAI 
although these observations are based on expert opinion or non-randomized clinical 
trials [23–27]. Recurrence has been seen both after ATD and RAI with the former hav-
ing a significantly higher recurrence rate. Though the recurrence rates after RAI and 
surgery are not significantly different, multiple doses of RAI may be required for cure 
in a given patient [23]. In a meta-analysis involving 1402 patients across 5 continents, 
surgery had the lowest recurrence rates even though a sub total thyroidectomy was the 
procedure performed in those with available surgical records [27]. More over surgery 
avoids the long-term systemic side effects of ATD and radiation exposure of RAI. 
Though a matter of debate, patients having chosen surgery as a definitive treatment 
are likely to be more satisfied compared to RAI [5, 28]. Patients preference should 
always be taken into consideration. Patients are likely to browse the internet for more 
information. However, the both reliability and comprehension of available informa-
tion is occasionally questionable [29]. Hence, the treating physician should make 
available to the patient pertinent information so that patient can make an un biased 
decision which will further improve compliance and satisfaction to treatment.
8. Geographic variability in preferred treatment options
There are wide variations in the preferred first line treatment for GD. The choice 
is culmination of patient and physician preference along with disease status. In the 
US, RAI is likely to be the primary therapy though its popularity is decreasing. ATD 
are preferred in Latin America, Europe and Japan [30, 31]. Popularity of ATD has 
also surpassed RAI in New Zealand [32]. Once again ATD are the favored first line 
treatment in middle east and north African regions. Also, the physician practices 
were found to be that between European and American preferences, probably 
attributed to their training and affiliations [33].
9. Peri operative management
Imaging of thyroid is essential, and ultrasonography is useful. It aids in surgical 
planning and presence of nodule(s) mandates a fine needle aspiration cytology 
before surgery. Contrast enhanced CT scan (CECT) may be required for large 
goiters. Euthyroid state should be achieved in all patients before surgery [30]. This 
is achieved by ATD which is continued till the morning of surgery. Tachycardia if 
present is controlled by institution on beta blockers. The role of pre-operative Iodine 
solution remains controversial but the authors favor same [34]. Lugols Iodine/ 
collosal Iodine/SSKI is given thrice a day for 7–12 days prior to surgery. Iodine has 
been shown to decrease the vascularity the thyroid and makes the gland firmer. 
These changes aid the surgeon [35]. Guidelines suggested by various professional 
bodies aid in management and peri operative preparation of hyperthyroid patients 
of which American Thyroid Association (ATA) seems to be most commonly fol-
lowed. However, a study by Siddique Akram et al. found that adherence to ATA 
guidelines did not impact the outcome significantly but for increased intra operative 
tachycardia in patient not following ATA guidelines [36]. In fact, almost 28% of the 
cohort remained hyperthyroid at the time of surgery but no adverse impact was 
noted. Pre-operative vit D deficiency may result in higher incidence of post thyroid-
ectomy hypocalcemia [37]. Vit D and calcium may be supplemented in pre-opera-
tive period to reduce the incidence of post-surgery hypocalcemia [38, 39]. However 
unpublished data from authors have not shown any advantage of supplementation 
in reducing post TT hypocalcemia.
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Surgery is best performed by a high-volume surgeon in a specialized unit for 
best outcome [40]. Surgical adjuncts may be utilized as per need, availability, cost 
constraints and surgeon preference. Meticulous surgery parathyroid vascularity is 
of prime importance in bettering outcomes. Parathyroid auto transplantation after 
inadvertent injury or excision results in increased occurrence of temporary hypo-
calcemia but not permanent hypocalcemia [41].
Post thyroidectomy, patients are kept under observation for development of 
hypocalcemia or risk of bleed. These were traditionally said to occur at a higher 
incidence after surgery performed for GD [41]. Hungry bone syndrome, Vitamin 
D deficiency, female sex are factors that have been associated with apparent higher 
incidence of post TT hypocalcemia in GD. However, recent studies have concluded 
that hypocalcemia and post thyroidectomy bleed do not occur at a significantly 
higher rate in GD [42]. Post TT PTH may be evaluated as per institutional protocols 
to predict hypocalcemia and plan early discharge. PTH gradient is said to better 
predict hypocalcemia than any single value. Same day safe discharge of patients 
is feasible for GD after surgery with no adverse outcomes [43]. ATD are discon-
tinued and Beta blockers if prescribed are tapered gradually in the post-operative 
period. Thyroxine supplement is started between POD1–7 at a dose if 1.6–2.1 
microgram/Kg.
10. Rapid preparation for graves surgery
Patients are usually rendered euthyroid by ATD to reduce peri operative 
complications with thyroid storm being the most dreaded one. However, a subset 
of patients may require urgent/emergent surgery in view of significant compres-
sion, intolerance of drugs or failure of drugs. Such patients may be subjected to a 
rapid preparation protocol where in two or more of dexamethasone, beta blocker, 
sodium iopodate, iopanoic acid, collosal/lugols Iodine, cholestyramine, iodinated 
radiographic contrast agent, lithium and ATD if tolerated are used for 10–12 days 
prior to anticipated surgery. No significantly increased morbidity has been reported 
after surgery in the rapidly prepared patients and this strategy is required and is 
feasible in a subset of patients [44–46]. The occurrence of thyroid storm is rare 
and biochemically hyperthyroid patients may undergo thyroidectomy safely if the 
surgeon and anesthetist are comfortable [47]. However, the consensus remains that 
the outcome is best when surgery is performed on a euthyroid patient.
11. Choice of surgical procedure
Bilateral subtotal thyroidectomy (STT), Dunhill procedure (DP), near total 
thyroidectomy (NTT) and total thyroidectomy (TT) are the four procedures that 
have been or are being performed for GD. STT, DP, NTT were the procedure of 
choice till 21st century due to said higher incidence of hypoparathyroidism, nerve 
damage or hematoma [15]. However, these have not been verified in recent large 
studies or meta-analysis [48]. A retrospective cohort study 8032 patients of benign 
thyroid disease having undergone STT or TT found no difference in temporary of 
permanent nerve damage and permanent hypoparathyroidism though temporary 
hypocalcemia was significantly higher in TT compared to TT (13.12% Vs. 2.7%) 
[49]. A similar trend has been seen in most other studies. TT for GD has been found 
to have lower rates of recurrent hyperthyroidism compared to other procedures 
(STT more than DP) [17, 50]. The nerve damage rates have been higher however 
hypocalcemia rates have been slightly higher though they do not reach statistical 
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significance [50]. The choice of surgical procedure did not have a difference in their 
effect on Graves’ ophthalmopathy [17, 50]. RAI with steroid cover was found to 
be not inferior to surgery. The TT performed by trained surgeons at high volume 
center have no higher rates of these morbid complications. More and more TT are 
now being performed for benign diseases throughout world. Thomas WT et al. in an 
analysis of nationwide in patient analysis in US noted an increase in TT for benign 
diseases from 17.6% in 1993–1997 to 39.6 in 2003–2007 [51]. This trend is seen across 
the globe even in less developed regions [40, 52]. However TT may be avoided in in 
situations where lifelong thyroxine supplements may be un reliable, more com-
mon in the lesser developed countries [3]. Never the less, 2016 ATA guidelines for 
Hyperthyroidism suggest that a NTT of TT should be performed for GD if surgery 
is being contemplated [30].
12. Disadvantages of surgery
Patients would require lifelong thyroxine replacement after thyroidectomy and 
compliance may be an issue in some. Also, potential risk of permanent hypopara-
thyroidism and recurrent laryngeal nerve damage or neck hematoma are present. 
However, in trained hands, their incidence is no higher than after surgery for 
euthyroid goiters. Vis a vis ATD and RAI, surgery is the least cost effective first line 
treatment of Grave’s disease [53, 54]. In recurrent GD after ATT, surgery was more 
cost effective than RAI or lifelong ATD to a large extent [55]. The cost implications 
are likely to vary across the globe depending on various factors.
13. Surgical approach to thyroid
Though conventionally, open thyroidectomy through a transverse collar inci-
sion is the standard of care, heightened cosmetic demands of patients along with 
refinements in surgical instruments and surgical training has resulted in significant 
shift favoring minimally invasive procedures. Meta-analysis of 846 cases between 
1999–2011 by Zhang et al. concluded that endoscopic thyroidectomy provides better 
cosmetic satisfaction along with lesser blood loss at the expense of higher costs and 
operative time with acceptable rates of hypocalcemia and nerve compromise [56].
Robotic surgery is now a feasible option for grave’s disease with comparable 
complication rates [57]. Also, larger glands can be excised via robotic technique. 
Retrospective analysis of 44 robotic TT via bilateral axillo- breast approach was no 
inferior when compared to 144 cases of open thyroidectomy in terms of recurrence, 
hypocalcemia and nerve damage on prolonged follow up of 35 months [58]. This is 
now a valid option for those concerned about cosmesis.
14. Conclusion
Etiology of hyperthyroidism has to be determined thoroughly to determine 
the line of management. Radioactive iodine ablation (RAI) or surgery is the main 
modality of treatment in GD. Anti-thyroid drug is essential to make the patient 
euthyroid prior to definitive therapy. Prompt discussion with patients regarding 
delayed outcome and retreatment in those who opt for RAI is mandatory. Surgical 
treatment of choice in the form of NTT or TT ought to be performed in a high-
volume centre to reduce complication and recurrence. Toxic adenoma and TMNG 
are managed similarly to GD i.e., rendering euthyroid with ATDs, followed by 
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definitive therapy. Extent of surgery in toxic solitary adenoma depends on radiol-
ogy, nuclear imaging after malignancy is ruled out. Newer ablative therapies like 
RFA, EA, LTA are considered as a substitute for definitive therapy in selective 
patients. Nonetheless malignancy should always be treated by surgery.
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